Literature DB >> 24824074

14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

Maria Laura Bertolaccini1, Olga Amengual2, Laura Andreoli3, Tatsuya Atsumi2, Cecilia B Chighizola4, Ricardo Forastiero5, Philip de Groot6, Gabriella Lakos7, Marc Lambert8, Pierluigi Meroni9, Thomas L Ortel10, Michelle Petri11, Anisur Rahman12, Robert Roubey13, Savino Sciascia14, Melissa Snyder15, Anne E Tebo16, Angela Tincani3, Rohan Willis17.   

Abstract

Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in the presence of at least one of the two major clinical manifestations (i.e. thrombosis or pregnancy morbidity) of the syndrome. However, several other autoantibodies shown to be directed to other proteins or their complex with phospholipids have been proposed to be relevant to APS but their clinical utility and their diagnostic value remains elusive. This report summarizes the findings, conclusions and recommendations of the "APS Task Force 3-Laboratory Diagnostics and Trends" meeting that took place during the 14th International Congress on Antiphospholipid Antibodies (APLA 2013, September 18-21, Rio de Janeiro, RJ, Brazil).
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiprothrombin antibodies; Domain I; IgA; Lupus anticoagulant; Risk; aCL

Mesh:

Substances:

Year:  2014        PMID: 24824074     DOI: 10.1016/j.autrev.2014.05.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  75 in total

Review 1.  Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.

Authors:  Mirjana Bećarević
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 2.  Treatment of catastrophic antiphospholipid syndrome.

Authors:  Nayef M Kazzaz; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

3.  Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Marija Sarić; Ljudmila Stojanovich; Duško Mirković; Violeta Dopsaj; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2018-06-12       Impact factor: 2.980

4.  Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data.

Authors:  Mirjana Bećarević; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2016-07-01       Impact factor: 2.980

Review 5.  The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

6.  Double positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data.

Authors:  Mirjana Bećarević; Duško Mirković; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2016-10-14       Impact factor: 2.980

7.  In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis.

Authors:  He Meng; Srilakshmi Yalavarthi; Yogendra Kanthi; Levi F Mazza; Megan A Elfline; Catherine E Luke; David J Pinsky; Peter K Henke; Jason S Knight
Journal:  Arthritis Rheumatol       Date:  2017-03       Impact factor: 10.995

Review 8.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

9.  The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Ljudmila Stojanović; Svetlana Ignjatović; Violeta Dopsaj
Journal:  Clin Rheumatol       Date:  2016-03-14       Impact factor: 2.980

Review 10.  Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up.

Authors:  Laurent Simonin; Elisabeth Pasquier; Christophe Leroyer; Divi Cornec; Julie Lemerle; Boutahar Bendaoud; Sophie Hillion; Jacques-Olivier Pers; Francis Couturaud; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.